Live
- JAIN International Residential School, Bengaluru jointly with The Sports School to announce India’s First Integrated Scholarship Future25
- Sale certificate issued in pursuance to a court's auction not required to be stamped: Supreme Court
- Andhra Pradesh: Jagan flays Chandrababu-led govt for neglect of education
- Sri Lanka issues flood warnings for 12 flood-prone river basin areas
- IPL 2025 Auction: Venkatesh Iyer sold to KKR for Rs 23.75 cr, Stoinis joins PBKS for Rs 11 crore
- Kharge to lead Opposition strategy meeting as Parliament session kicks off on Monday
- Three killed in firing as violence breaks out amid Sambhal mosque survey in UP
- IPL 2025 Auction: Ravichandran Ashwin, Rachin Ravindra return to Chennai Super Kings
- Manipur: After over a week's closure, regular classes to resume in educational institutions
- Govt open to discuss all issues, says Kiren Rijiju on eve of Winter Session of Parliament
Biocon Q4FY22 Results: Consolidated Profit rose 4.21% YoY to Rs 283.9 crore
Biocon, a biopharmaceutical company, has reported a 4.21% YoY decline in the consolidated profit at Rs 283.9 crore for the quarter ended March 31, 2022.
Biocon, a biopharmaceutical company, has reported a 4.21% YoY decline in the consolidated profit at Rs 283.9 crore for the quarter ended March 31, 2022. It had posted a profit of Rs 296.4 crore posted in the corresponding quarter of the previous financial year.
The company's revenue from operations grew 30.76% to Rs 2,408.8 crore against Rs 1,842.1 crore posted last year. Its EBITDA grew 35.9% YoY to Rs 591.9 crore in the reported quarter against Rs 435.7 crore posted last year. Its margin grew to 24.6% in Q4FY22 compared to Rs 23.7% posted in Q4FY21.
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics, said, "FY22 was a transformational year for Biocon. Key strategic moves in our Biosimilars business position us for long-term growth and value creation for our stakeholders." She added, "We believe that the two strategic transactions, with Viatris and Serum Institute Life Sciences, will position Biocon Biologics as a world leading, unique, fully integrated biologics company with a strong differentiated portfolio of biosimilars and vaccines."
Besides, the Board of Directors of the company has recommended a final dividend at the rate of 10% i.e. Re 0.50 per equity share of face value of Rs 5 each for the financial year ended March 31, 2022. The record date for payment of final dividend is July 1, 2022. The dividend will be paid within 30 (thirty) days from the date of shareholders' approval at the ensuing 44th Annual General Meeting (AGM) which is scheduled to be held on Friday, July 29, 2022.
The board also approved the appointment of Ms. Naina Lal Kidwai as an Additional Director (Category: Non-Executive and Independent Director) of the Company with effect from the conclusion of the Board Meeting i.e. April 28, 2022, till the conclusion of the ensuing 44th AGM of the Company.
Further, Ms. Naina Lal Kidwai has also been appointed as an Independent Director of the Company, not liable to retirement by rotation, with effect from the conclusion of the Board Meeting i.e. April 28, 2022, till the conclusion of the 47th AGM proposed to be held in the year 2025, subject to the approval of shareholders of the Company.
